4.5 Article

Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis

Journal

OSTEOPOROSIS INTERNATIONAL
Volume 32, Issue 2, Pages 363-375

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s00198-020-05601-y

Keywords

Atypical femoral fracture; Beaking; Bisphosphonate; Femoral localized periosteal thickening; Glucocorticoid; Rheumatoid arthritis

Funding

  1. Lilly Research Grant Program for Bone & Mineral Research

Ask authors/readers for more resources

The study found that the incidence of localized periosteal thickening in patients with rheumatoid arthritis was not high, but two patients developed incomplete atypical femoral fractures. Higher-dose prednisolone and higher-dose methotrexate were significant risk factors for LPT.
The incidence of localized periosteal thickening (LPT, also termed beaking) of the lateral cortex that often precedes an atypical femoral fracture (AFF) was not high in patients with rheumatoid arthritis (RA) but incomplete AFFs developed in two patients. Higher-dose prednisolone was a significant risk factor for LPT in patients with RA. Introduction Atypical femoral fractures (AFFs) are stress fractures; bisphosphonate (BP) use is a major risk factor for the development of such fractures. Localized periosteal thickening (LPT, also termed beaking) of the lateral cortex often precedes a complete or incomplete AFF. We evaluated the incidence of latent LPT in patients with rheumatoid arthritis (RA), to evaluate LPT progression, and to define LPT risk factors. Methods A total of 254 patients with RA were included; all underwent annual X-ray evaluation, dual-energy X-ray absorptiometry, and analyses of serum and bone metabolic markers for 2-3 years. LPT of the lateral cortex was sought in femoral X-rays. Results The incidence of LPT was 2.4% (6/254). Among patients on both BP and prednisolone (PSL) at enrollment, the incidence was 2.3% (3/131). Two femurs of two patients with LPT developed incomplete AFFs; LPT was extensive and associated with endosteal thickening. One patient had been on BP and PSL and microscopic polyangiitis was comorbidity. The other was on a selective estrogen receptor modulator and PSL. A daily PSL dose >5 mg (OR 11.4; 95%CI 2.15-60.2;p = 0.004) and higher-dose methotrexate (OR 1.22; 95%CI 1.01-1.49;p = 0.043) were significant risk factors for LPT. Conclusions The incidence of latent LPT was not high (2.4%) but incomplete AFFs developed in two RA patients. Higher-dose PSL because of a comorbid disease requiring glucocorticoid treatment other than RA or refractory RA were risk factors for LPT; X-ray screening for latent LPT would usefully prevent complete AFFs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available